FDA
-
-
-
-
-
-
-
Teva bids $57.5M for BioXcel agitation drug in bankruptcy sale
-
-
-
-
-
-
-
Medincell: UZEDY®: Record Q2 Net Sales of $77M, Up 43% YoY; Teva Raises 2026 Outlook
-
-
-
-
-
-
-
EMA accepts Teva application for long-acting olanzapine schizophrenia drug
-
-
-
-
-
-
-
FDA accepts Teva's drug application for monthly schizophrenia treatment
-
-
-
-
-
-
-
Teva's AJOVY reduces migraine days in children in clinical trial
-
-
-
-
-
-
-
Teva submits FDA application for monthly schizophrenia injection
-
-
-
-
-
-
-
FDA Approves Expanded Indication for UZEDY® (risperidone) Extended-Release Injectable Suspension as a Treatment for Adults Living with Bipolar I Disorder
-
336,479 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


